Jetzt anmelden und diskutieren
Registrieren
Login
Aufrufe: 279
Together, these data reinforce Novo Nordisk’s position as the scientific leader in obesity treatment, with the broadest portfolio of approved and pipeline GLP-1-based therapies.
“Novo Nordisk is looking forward to presenting compelling data at ECO, which highlight benefits of our treatments for people living with obesity, including women dealing with health challenges during all phases of menopause,” said Martin Holst Lange, chief scientific officer and head of Research & Development at Novo Nordisk. “We look forward to discussing these data and, most importantly, supporting women and all patients suffering from obesity.”
Select Novo Nordisk abstracts to be presented at ECO 2026, 12–15 May (Istanbul, Turkey; GMT +3):
Wegovy® pill – oral semaglutide 25 mg (OASIS 4, ORION, OPTIC)
Werbung| Strategie | Hebel | |||
| Steigender Kurs |
Call
|
5
|
10
|
20
|
| Fallender Kurs |
Put
|
5
|
10
|
20
|
Wegovy® – semaglutide 2.4 mg (SELECT)
Wegovy® – semaglutide 7.2 mg (STEP UP)
Wegovy® real-world evidence:
CagriSema 2.4 mg/2.4 mg (REDEFINE):
About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just a lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.
About Wegovy®
Wegovy® is approved as once-daily Wegovy® pill (semaglutide tablet 25 mg) and once-weekly Wegovy® injections (semaglutide 1.7 mg, 2.4 mg and 7.2 mg) by the FDA. Wegovy® is approved as a once-weekly injection (semaglutide 2.4 mg and 7.2 mg) by the EMA and by other regulatory authorities worldwide. The Wegovy® pill is currently pending marketing approval from the EMA and other regulatory authorities.
Wegovy® is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight and in the presence of at least one weight-related comorbid condition, and approved by the FDA to reduce the risk of major adverse cardiovascular events, such as death, heart attack or stroke in adults with known heart disease and either obesity or overweight. Furthermore, Wegovy® injection is indicated to reduce excess body weight and maintain long-term weight reduction in paediatric patients aged 12 years and older. It is approved by the FDA for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not in those with cirrhosis of the liver.
About CagriSema
Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, increasing feelings of fullness and thereby help people eat less and reduce their calorie intake.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Max Ung +45 3077 6414 mxun@novonordisk.com |
| Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com | Alex Bruce +45 3444 2613 axeu@novonordisk.com |
| Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com | Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Attachment
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
